These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12689409)

  • 1. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.
    Ketas TJ; Klasse PJ; Spenlehauer C; Nesin M; Frank I; Pope M; Strizki JM; Reyes GR; Baroudy BM; Moore JP
    AIDS Res Hum Retroviruses; 2003 Mar; 19(3):177-86. PubMed ID: 12689409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.
    Ketas TJ; Frank I; Klasse PJ; Sullivan BM; Gardner JP; Spenlehauer C; Nesin M; Olson WC; Moore JP; Pope M
    J Virol; 2003 Feb; 77(4):2762-7. PubMed ID: 12552019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.
    Tremblay CL; Giguel F; Kollmann C; Guan Y; Chou TC; Baroudy BM; Hirsch MS
    Antimicrob Agents Chemother; 2002 May; 46(5):1336-9. PubMed ID: 11959565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.
    Tsamis F; Gavrilov S; Kajumo F; Seibert C; Kuhmann S; Ketas T; Trkola A; Palani A; Clader JW; Tagat JR; McCombie S; Baroudy B; Moore JP; Sakmar TP; Dragic T
    J Virol; 2003 May; 77(9):5201-8. PubMed ID: 12692222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
    Torre VS; Marozsan AJ; Albright JL; Collins KR; Hartley O; Offord RE; Quiñones-Mateu ME; Arts EJ
    J Virol; 2000 May; 74(10):4868-76. PubMed ID: 10775626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV entry and fusion inhibitors.
    Chantry D
    Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.
    Ayouba A; Cannou C; Nugeyre MT; Barré-Sinoussi F; Menu E
    Retrovirology; 2008 Mar; 5():31. PubMed ID: 18377645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemofiltrate CC chemokine 1[9-74] causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages.
    Münch J; Ständker L; Pöhlmann S; Baribaud F; Papkalla A; Rosorius O; Stauber R; Sass G; Heveker N; Adermann K; Escher S; Klüver E; Doms RW; Forssmann WG; Kirchhoff F
    Antimicrob Agents Chemother; 2002 Apr; 46(4):982-90. PubMed ID: 11897579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.
    Strizki JM; Xu S; Wagner NE; Wojcik L; Liu J; Hou Y; Endres M; Palani A; Shapiro S; Clader JW; Greenlee WJ; Tagat JR; McCombie S; Cox K; Fawzi AB; Chou CC; Pugliese-Sivo C; Davies L; Moreno ME; Ho DD; Trkola A; Stoddart CA; Moore JP; Reyes GR; Baroudy BM
    Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12718-23. PubMed ID: 11606733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
    Heredia A; Gilliam B; Latinovic O; Le N; Bamba D; Devico A; Melikyan GB; Gallo RC; Redfield RR
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2489-96. PubMed ID: 17485501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors.
    Billick E; Seibert C; Pugach P; Ketas T; Trkola A; Endres MJ; Murgolo NJ; Coates E; Reyes GR; Baroudy BM; Sakmar TP; Moore JP; Kuhmann SE
    J Virol; 2004 Apr; 78(8):4134-44. PubMed ID: 15047829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyses of anti-HIV type 1 activity of a small CCR5 peptide antagonist.
    Wang FY; He SY; Zhang ZJ; He LF; Chen XW; Teng T
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1111-5. PubMed ID: 21375388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.
    Repits J; Öberg M; Esbjörnsson J; Medstrand P; Karlsson A; Albert J; Fenyö EM; Jansson M
    J Gen Virol; 2005 Oct; 86(Pt 10):2859-2869. PubMed ID: 16186242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attachment and fusion inhibitors potently prevent dendritic cell-driven HIV infection.
    Frank I; Robbiani M
    J Acquir Immune Defic Syndr; 2011 Mar; 56(3):204-12. PubMed ID: 21084994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1.
    Heredia A; Gilliam B; DeVico A; Le N; Bamba D; Flinko R; Lewis G; Gallo RC; Redfield RR
    AIDS; 2007 Jun; 21(10):1317-22. PubMed ID: 17545708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.
    Marozsan AJ; Torre VS; Johnson M; Ball SC; Cross JV; Templeton DJ; Quiñones-Mateu ME; Offord RE; Arts EJ
    J Virol; 2001 Sep; 75(18):8624-38. PubMed ID: 11507208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.